Eric Lefkofsky

Tempus AI's $1.5 billion acquisition of Personalis, announced July 20, 2026, looks prescient after Moderna and Merck reported positive Phase 3 results for mRNA-4157, a personalized cancer vaccine that…

Tempus AI has agreed to acquire Personalis, Inc. for $1.5 billion, or $16.25 per share, gaining its NeXT Personal minimal residual disease blood test for cancer detection. The deal targets a $20 billi…